Comparison · NCT01884675-1f10877e
Ambrisentan 5mg vs Placebo: Number of Participants With Significant Liver Events at Weeks 4, 8, 12, and 16/Early Withdrawal
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Ambrisentan 5mg vs Placebo: Number of Participants With Significant Liver Events at Weeks 4, 8, 12, and 16/Early Withdrawal. Trial comparisons, record NCT01884675-1f10877e. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01884675-1f10877e
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0 | 0 | 0.184 | wilson | |
| Risk in group 2 | 0 | 0 | 0.194 | wilson | |
| Risk difference, group 1 minus group 2 | 0 | -0.194 | 0.184 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | log | a group has no participants with the outcome | |||
| Odds ratio, group 1 over group 2 | log | a cell of the two-by-two table is zero | |||
| Number needed to treat | from the risk difference interval | the two groups' risks are equal |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Ambrisentan 5mg | Participants received an ambrisentan 5milligram (mg) tablet, once daily for a period of 16 weeks. | 0 | 17 | OG001 |
| Group 2 | Placebo | Participants received a matching placebo tablet once daily for a period of 16 weeks. | 0 | 16 | OG000 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Number of Participants With Significant Liver Events at Weeks 4, 8, 12, and 16/Early Withdrawal
- Description
A significant liver chemistry result is defined as any result which met the stopping criteria defined in the study protocol. Liver events were assessed at Screening, Baseline, Weeks 4, 8, 12, and 16/Early Withdrawal. Number of participants who reported a significant liver chemistry result are presented.
- Time frame
- Weeks 4, 8, 12, and 16/Early Withdrawal
- Population
- ITT Population
Source ClinicalTrials.gov
Trial
- Title
- Ambrisentan for Inoperable Chronic Thromboembolic Pulmonary Hypertension.
- NCT number
- NCT01884675
- Phases
- PHASE3
- Conditions
- Hypertension
- Interventions
- Ambrisentan 5 mg, Placebo
- Lead sponsor
- GlaxoSmithKline
- Results first posted
- 2015-12-16
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT01884675?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT01884675-1f10877e